Browsing: Disease Area > Bacterial
Globally, shigella is reported to be the third largest cause of diarrheal mortality in the under-fives. We take a look at some of the vaccines that have made it to clinical development and some of the challenges still facing this diarrheal disease.
Small-molecule compounds designed to tag the cell surface of Gram-negative bacteria and trigger an immunological response have shown promise.
Antibiotic effectiveness can be restored if utilized in the correct combination with each other, non-antibiotic adjuvants or even food additives.
In this interview we take a look at cholera outbreak situations and the strategies required to tackle them as we talk to Martin Mengel following his presentation at ECCMID.
The US FDA has approved Zemdri for use in adults with complicated urinary tract infections; however, the agency has also issued a response for bloodstream infections noting there isn’t substantial evidence of Zemdri’s effectiveness.
Recent technological advancements have allowed organoids to become a viable research tool for a wide range of development and disease models. Here, we look at some of the research that’s been done in infectious diseases and delve into what the future of organoids might look like.
Through a process of elimination, researchers have identified membrane surface proteins on T. pallaidum, which can be targeted by immune antibodies.
Whole-genome sequencing has been used to demonstrate that carbapenem resistance can be transferred among unrelated bacteria species in a healthcare setting.